{
    "clinical_study": {
        "@rank": "65631", 
        "arm_group": [
            {
                "arm_group_label": "Cinacalcet HCl", 
                "arm_group_type": "Experimental", 
                "description": "50% of subjects will receive cinacalcet in addition to standard of care, which can include vitamin D sterols, calcium supplements or phosphate binders"
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "arm_group_type": "Active Comparator", 
                "description": "50% of subjects will receive standard of care, which can include vitamin D sterols, calcium supplements or phosphate binders."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase 3, 24-week, randomized, multicenter, open-label, controlled study.  subjects\n      will be randomized into one of two treatment arms; oral administration of cinacalcet daily\n      in addition to standard of care treatment arm or a standard of care arm. Randomization will\n      be stratified by age group. All subjects receive standard of care which can include therapy\n      with Vitamin D sterols, calcium supplementation, and phosphate binders."
        }, 
        "brief_title": "A Study to Assess the Efficacy and Safety of Cinacalcet in Pediatric Subjects With SHPT and CKD on Dialysis", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Kidney Disease, Secondary Hyperparathyroidism", 
        "condition_browse": {
            "mesh_term": [
                "Hyperparathyroidism", 
                "Hyperparathyroidism, Secondary", 
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 6 - < 18 years\n\n          -  Diagnosis of SHPT with the mean of the two consecutive central laboratory iPTH values\n             \u2265 300 pg/mL during screening\n\n          -  Corrected calcium value of \u2265 8.8 mg/dL during screening\n\n          -  Diagnosis of CKD, receiving either hemodialysis or peritoneal dialysis, for \u2265 30 days\n             prior to screening\n\n          -  Parent or legally acceptable representative has provided written informed consent and\n             subject has provided written assent when required by institutional guidelines\n\n        Exclusion Criteria:\n\n          -  History of congenital long QT syndrome, second or third degree heart block,\n             ventricular tachyarrhythmias or other conditions associated with prolonged QT\n             interval\n\n          -  Corrected QT interval (QTc) > 500 ms, using Bazett's formula\n\n          -  QTc \u2265 450 to \u2264 500 ms, using Bazett's formula, unless written permission to enroll is\n             provided by the investigator after consultation with a pediatric cardiologist\n\n          -  Use of grapefruit juice, herbal medications, or potent CYP 3A4 inhibitors (eg,\n             erythromycin, clarithromycin, ketoconazole, itraconazole)\n\n          -  Use of concomitant medications that may prolong the QTc interval (eg, ondansetron,\n             albuterol)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02138838", 
            "org_study_id": "20130356", 
            "secondary_id": "2013-004958-18"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cinacalcet HCl", 
                "description": "Subjects will receive oral administration of cinacalcet daily in addition to standard of care therapy. Cinacalcet will be provided in 5 mg capsules that must be sprinkled onto soft food or suspended into a liquid suspension for administration and 30 mg tablets for swallowing. The protocol specified doses for use in this study are: 2.5, 5, 10, 15, 30, 60, 90, 120, and 180 mg. The maximum dose of cinacalcet that will be administered at any time during the study will be 2.5 mg/kg/day based on the subject's dry weight during randomization or 180 mg daily, whichever is lower.  The treatment period consists of Weeks 1 - 20. Following completion of the treatment period, all subjects will enter a 4 week safety follow-up period through Week 24.", 
                "intervention_name": "Cinacalcet HCl", 
                "intervention_type": "Drug", 
                "other_name": "Cinacalcet HCl"
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "description": "At the investigator's discretion, subjects will receive standard of care, which can include vitamin D sterols, calcium supplements or phosphate binders. The treatment period consists of Weeks 1 - 20. Following completion of the treatment period, all subjects will enter a 4 week safety follow-up period through Week 24.", 
                "intervention_name": "Standard of Care", 
                "intervention_type": "Dietary Supplement", 
                "other_name": [
                    "Vitamin D sterols (e.g. calcitriol, paricalcitol), calcium supplementation and phosphate", 
                    "binders (calcium based and non-calcium based)."
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Chronic Kidney Disease, Secondary Hyperparathyroidism, Dialysis, Pediatric", 
        "lastchanged_date": "May 26, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis", 
        "overall_contact": {
            "last_name": "Amgen Call Center", 
            "phone": "866-572-6436"
        }, 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Achievement of a \u2265 30% reduction from baseline in mean plasma iPTHduring the efficacy assessment period (EAP), defined as Week 17 - 20", 
            "safety_issue": "Yes", 
            "time_frame": "Week 17-20"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02138838"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Achievement of a mean iPTH \u2264 300 pg/mL (31.8 pmol/L) during the EAP", 
                "safety_issue": "Yes", 
                "time_frame": "Week 17-20"
            }, 
            {
                "measure": "Percent change in iPTH from baseline to the mean value during the EAP", 
                "safety_issue": "Yes", 
                "time_frame": "Week 17-20"
            }, 
            {
                "measure": "Change in corrected total serum calcium from baseline to the mean value during the EAP", 
                "safety_issue": "Yes", 
                "time_frame": "Week 17-20"
            }, 
            {
                "measure": "Change in serum phosphorus from baseline to the mean value during the EAP", 
                "safety_issue": "Yes", 
                "time_frame": "Week 17-20"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}